ELIFast found to have specificity and sensitivity of 99.33 per cent and 92 per cent respectively
Cipla announced the commercialisation of antibody detection kits for COVID-19 in India in partnership with KARWA under the technology transfer from the Indian Council of Medical Research (ICMR).
As part of this collaborative effort, Cipla will be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detection ELISA that will be manufactured by KARWA. ICMR has provided the requisite technological know-how and process for developing the test kits to the approved manufacturers. The product will be marketed under the brand name ‘ELIFast’. Cipla’s expansive distribution network will help in ensuring the seamless supply of kits across the country. Supply will be undertaken through the channels approved by ICMR, to ensure equitable access.
ELIfast has been validated and approved by ICMR and the National Institute of Virology (NIV), Pune. It is found to have specificity and sensitivity of 99.33 per cent and 92 per cent respectively. The kit is user friendly with a simple protocol with ready-to-use reagents and is compatible with common ELISA equipment.
- Advertisement -